FindMyKOL
Clinical trialNCT03827018CompletedPhase 2Interventional

KPL-301 for Subjects With Giant Cell Arteritis

SponsorKiniksa Pharmaceuticals, Ltd.Enrollment70Giant Cell Arteritis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Site 2102

    Kogarah, Australia

  • Site 2105

    Nedlands, Australia

  • Site 2106

    Parkville, Australia

  • Site 2101

    Victoria Park, Australia

  • Site 2104

    Woodville South, Australia

Belgium
  • Site 2204

    Brussels, Belgium

  • Site 2202

    Leuven, Belgium

  • Site 2201

    Liège, Belgium

  • Site 2203

    Yvoir, Belgium

Croatia
  • Site 2303

    Zagreb, Croatia

Estonia
  • Site 2401

    Tallinn, Estonia

  • Site 2402

    Tartu, Estonia

Germany
  • Site 2502

    Tübingen, Baden-Wurttemberg, Germany

  • Site 2504

    Erlangen, Bavaria, Germany

  • Site 2507

    Freiburg im Breisgau, Germany

  • Site 2506

    Hamburg, Germany

  • Site 2503

    Hanover, Germany

  • Site 2508

    Jena, Germany

  • Site 2501

    Kirchheim unter Teck, Germany

Ireland
  • Site 2601

    Dublin, Ireland

Italy
  • Site 2703

    Milan, Italy

  • Site 2701

    Pieve Emanuele, Italy

  • Site 2702

    Reggio Emilia, Italy

  • Site 2704

    Udine, Italy

Netherlands
  • Site 2802

    Groningen, Netherlands

  • Site 2801

    Rotterdam, Netherlands

New Zealand
  • Site 2902

    Christchurch, New Zealand

  • Site 2901

    Wellington, New Zealand

Poland
  • Site 1002

    Krakow, Poland

Serbia
  • Site 1101

    Belgrade, Serbia

  • Site 1102

    Belgrade, Serbia

  • Site 1103

    Belgrade, Serbia

Slovenia
  • Site 1201

    Ljubljana, Slovenia

Spain
  • Site 1303

    A Coruña, Spain

  • Site 1301

    Barcelona, Spain

  • Site 1304

    Bilbao, Spain

  • Site 1302

    Santa Cruz de Tenerife, Spain

United Kingdom
  • Site 1604

    Edinburgh, United Kingdom

  • Site 1603

    Essex, United Kingdom

  • Site 1602

    London, United Kingdom

9 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Prednisone
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Sept 2018
Primary completion
13 Aug 2020
Completion
25 Nov 2020
Last update posted
23 Oct 2023
Registered enrollment
70
Registry id
NCT03827018
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.